Healthcare

Seidler Equity Partners IX held a first and final close last month at its $1.6bn hard-cap, sources told Buyouts, up 28% from its predecessor.

It is still possible to build, transform and exit businesses in this unsettled market, but quality matters more than ever, says Partners Group’s Ben McLean.

After a surge in interest around the covid-19 pandemic, it has been a mixed picture for life sciences and biotech-focused PE fundraising and capital deployment.

'Court Square has sent back $7.4bn to its LPs since 2022, the year the Fed began raising rates,' president and managing partner Chris Bloise tells Buyouts.

Founder and managing partner Rob Wolfson set up Aphias last year to make control investments in lower mid-market companies in healthcare services and essential services sectors.

The platform boasts an regulatory approval rate of nearly twice the industry average, division head Nicholas Galakatos tells Buyouts.

GL China Opportunities Fund V was launched in September 2025, aiming to raise $800m, and will mainly target buyout investments.

Demographic change and a shift from hospital to community-based care are creating investment opportunities for those with the right expertise, says Nihon PMI Partners CEO Satoshi Hamada.

Opportunity abounds in the small and mid-cap space, where companies are ripe for transformation initiatives, say Koji Sasaki and Toshihide Matsuda at T Capital Partners.